SQ-LIP-000020 · v1.5 (archived) · View current version →
How does lipedema affect quality of life, depression, and anxiety in affected patients?
Also asked as
- What impact does lipedema have on the wellbeing, depression, and anxiety levels of people who have it?
- In patients with lipedema, what are the effects on quality of life and on symptoms of depression and anxiety?
- lipedema effects quality of life depression anxiety patients
- To what extent does living with lipedema influence mental health, including depression and anxiety, and overall quality of life?
Lipedema is consistently associated with substantially reduced quality of life and elevated anxiety symptoms across multiple cohorts, with depression also commonly reported, though the strongest evidence comes from observational studies only. Whether the depression and anxiety burden is specific to lipedema or partly shared with obesity remains uncertain, and no controlled trials have tested any psychosocial intervention.
- Current answer
- Lipedema is consistently associated with substantially reduced health-related quality of life (HRQoL) and elevated depressive and anxiety symptoms across multiple countries and…
- Knowledge state
- Speculative · Evidence confidence: low (GRADE) · Stability: New
- Evidence
- 20 consistent · 0 conflicting · 2 refining / contextual
- ⚠ none indexed yet — the registry may under-detect disconfirming evidence (a known limitation)
- Evidence verification
- 24/24 sources independently verified
- Main limitation
- It remains uncertain whether elevated depression and anxiety in lipedema are disease-specific or substantially attributable to comorbid obesity; whether disease stage reliably…
- Latest change
- Answer recompiled after human curation of the claim set. · v1.5
- Knowledge freshness
- 83% recent · current evidence base
- Last updated
- 2026-06-02 · v1.5
| Health-related quality of life (HRQoL) | reduced | moderate (GRADE) | symptom-only |
| Consistently reduced vs population norms across SF-36/RAND-36/WHOQOL-BREF/EQ-5D; meta-analysis I²=83–93%. | |||
| Depression symptoms | increased | low (GRADE) | symptom-only |
| Elevated vs healthy/general-population controls; NOT significantly elevated vs overweight/obese controls (SCR-LIP-000177). | |||
| Anxiety symptoms | increased | low (GRADE) | symptom-only |
| Elevated vs healthy controls (64.4% HADS≥8; HAM-A 27.6 vs 5.0); NOT significantly elevated vs overweight/obese controls. | |||
| QoL variation by disease stage | mixed | low (GRADE) | symptom-only |
| Low-grade surveys suggest worse QoL at advanced stages; moderate-grade Swiss cohort found no stage-related difference. | |||
| Depression/anxiety after liposuction | improved | very_low (GRADE) | symptom-only |
| PHQ-4 improved post-liposuction in one uncontrolled prospective series; no RCT evidence; not disease-modifying. | |||
| QoL after liposuction | improved | very_low (GRADE) | symptom-only |
| FLZM health satisfaction improved markedly post-liposuction in one uncontrolled series; preliminary only. | |||
| Stigma and appearance-related distress | increased | low (GRADE) | symptom-only |
| Health-related stigma markedly elevated vs general population; independently predicts worse QoL (SCR-LIP-000174). | |||
Based on currently indexed evidence, lipedema is consistently associated with substantially reduced health-related quality of life (HRQoL) and elevated depressive and anxiety symptoms across multiple countries and cohorts. The evidence base comprises one moderate-grade systematic review/meta-analysis (SCR-LIP-000351), two moderate-grade cross-sectional cohorts (SCR-LIP-000357), multiple low-grade cross-sectional surveys and cohorts, narrative and scoping reviews, and small prospective liposuction case series; all are observational, precluding causal inference. QUALITY OF LIFE: The highest-quality evidence (moderate-grade meta-analysis, SCR-LIP-000351) confirms reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1); emotional well-being was also impaired (64.19 vs 73.2). This is corroborated by multiple low-grade cohorts: a Swedish national survey showed RAND-36 scores 25–35 points below age-matched norms (SCR-LIP-000354); a Dutch survey found RAND-36 59.3 vs 74.9 and EQ-5D-3L 66.1 vs 85 (SCR-LIP-000356); a Polish cohort (n=98) showed all WHOQOL-BREF domains below population values (SCR-LIP-000170); a large cohort (n=511) found WHOQOL-BREF global 60.5 with lowest physical (54.54) and psychological (51.91) domains (SCR-LIP-000355); a 44-woman Polish cohort found median SF-36 57.4/100 with lowest scores in general health (35) and energy/fatigue (45) (SCR-LIP-000178); and a Swiss cohort (n=239, moderate grade) found low QoL in 71.5% (PCS-SF36) and 67.4% (MCS-SF36) (SCR-LIP-000357). A 112-woman survey found WHOQOL-BREF averaging 3.12/5 and life satisfaction below midpoint (SCR-LIP-000353). DEPRESSION: Across low-grade cohorts, depression burden is consistently elevated but variable in magnitude. PHQ-9 means range from approximately 10.4 to 12.2, with 50.9–59.2% scoring ≥10 in several cohorts (SCR-LIP-000167, SCR-LIP-000170); a large cohort (n=511) found PHQ-9 mean 10.84 with 54% at moderate-to-severe risk (SCR-LIP-000355). Self-reported depression ranges from 13.5% (Swedish national survey, SCR-LIP-000354) to 22.7–43.6% in other surveys (SCR-LIP-000171, SCR-LIP-000169), and up to 48.3% in advanced-stage patients (SCR-LIP-000349). One small cohort (n=40) using HAM-D reported 87.5% at severe/high risk (SCR-LIP-000176), though this is a low-grade outlier. The moderate-grade Swiss cohort (n=239) found 23.4% with HADS depression ≥8 (SCR-LIP-000357). An important refinement: when lipedema patients are compared specifically with overweight/obese women rather than healthy or general-population controls, depression (BDI-II, HADS-D) shows NO significant difference before or after BMI adjustment (SCR-LIP-000177), suggesting some depression burden may overlap with obesity rather than being lipedema-specific. ANXIETY: Anxiety is consistently elevated. The moderate-grade Swiss cohort (n=239) found 64.4% with HADS anxiety ≥8 (SCR-LIP-000357). A Dutch survey found 42.0% reporting anxiety/depression on EQ-5D-3L (SCR-LIP-000356). A small case-control study (n=26) found markedly higher HAM-A scores (27.62 vs 4.96 in healthy controls), persisting after BMI adjustment (SCR-LIP-000172). One small cohort (n=40) reported 92.5% at severe/high anxiety risk (HAM-A mean 23.45, SCR-LIP-000176). However, when compared with overweight/obese women, anxiety (HADS-A) showed NO significant difference (SCR-LIP-000177), again suggesting partial overlap with obesity-related burden. CORRELATES AND PREDICTORS OF QoL: Across low-grade regression models, depression severity (PHQ-9 β=−0.36), appearance-related distress (DAS-24 β=−0.29), lower mobility, and symptom severity independently predict worse QoL, with models explaining 23.5–73% of variance (SCR-LIP-000173, SCR-LIP-000170); QoL-depression correlation reaches r=−0.775 (SCR-LIP-000355). Psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predict better QoL beyond symptom severity (SCR-LIP-000353). Health-related stigma is markedly elevated (Distress 49.5 vs 17.1–28.7 in general population) and correlates negatively with all RAND-36 domains (strongest for social functioning r=−0.54, SCR-LIP-000174). Pain severity and depressive symptoms are strongly correlated (rho=0.612, SCR-LIP-000169). Comorbid fibromyalgia is associated with significantly worse anxiety, depression, and QoL (SCR-LIP-000168). Longer disease duration correlates with worse depression (r=−0.415, SCR-LIP-000175); BMI correlates with depression and anxiety in some cohorts (SCR-LIP-000176) but QoL does not differ by BMI strata in others (SCR-LIP-000178). Low serum vitamin D inversely correlates with depression and anxiety in one small cohort (SCR-LIP-000176). DISEASE STAGE AND PSYCHOSOCIAL BURDEN: Evidence is inconsistent. Several low-grade surveys report worse depression, social isolation, and QoL at advanced stages (SCR-LIP-000349, SCR-LIP-000354, SCR-LIP-000355, r=0.55 for stage-QoL). However, the moderate-grade Swiss cohort (n=239) found NO significant variation in anxiety, depression, or QoL across disease stages (p>0.5, SCR-LIP-000357), which carries more weight than the low-grade stage-stratified surveys. EFFECT OF LIPOSUCTION ON PSYCHOSOCIAL OUTCOMES (preliminary, low-grade): A prospective single-arm case series found PHQ-4 total scores fell from 4.47 to 2.10 (p<0.001), anxiety subscale from 2.47 to 0.93, and QoL satisfaction (FLZM) from 45.77 to 88.00 post-liposuction (SCR-LIP-000352). A narrative review also cites improved depressive symptoms and body image after liposuction (SCR-LIP-000350). These findings are preliminary and uncontrolled; no RCT evidence exists. Liposuction does not modify the underlying disease. OVERALL EVIDENCE QUALITY: The evidence base is predominantly low-grade (cross-sectional, self-selected, uncontrolled, heterogeneous instruments, no blinding). The moderate-grade meta-analysis (SCR-LIP-000351) and moderate-grade Swiss cohort (SCR-LIP-000357) provide the strongest signals. High heterogeneity (I²=83–93% in the meta-analysis) limits pooled estimates. No RCTs or prospective controlled studies address psychosocial outcomes as primary endpoints.
A synthesis rendered from the currently indexed evidence — versioned, not a verdict.
⚙ AI consolidation: claude-sonnet-4.6 · 2026-06-02 — evidence-bounded; the AI does not opine
Answer recompiled after human curation of the claim set.
Knowledge freshness = share of the 24 indexed evidence sources from the last 5 years (newest 2025, oldest 2016) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
consistent conflicting refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline. The hollow ring marks the first time this topic appears in the literature.
Answer over time
Each node is a published version of the answer — open one to read the answer exactly as it stood then.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
Consistent claims
- SCR-LIP-000167 consistent
In a cross-sectional study of 43 Czech women with lipedema, 50.9% had moderate-to-severe depressive symptoms (PHQ-9 >=10) and WHOQOL-BREF scores were low across domains (psychological 46.3, physical 50.8), with the psychological domain most affected; specific physical symptoms (shortness of breath, muscle stiffness, appetite problems, fatigue, numbness) were significantly associated with depression severity.
Mental and physical health burden and quality of life in Czech women with lipedema — Kunzová et al. (2025) - SCR-LIP-000168 consistent
In a cross-sectional study of 354 women with lipedema, 35% met FMS criteria, and those with comorbid FMS had significantly higher anxiety (13.11 vs 9.87) and depression (10.23 vs 8.26) scores and lower SF-12 physical (35.37 vs 42.55) and mental (35.27 vs 40.38) quality-of-life scores (all p<0.001).
Prevalence of Fibromyalgia Syndrome in Women with Lipedema and Its Effect on Anxiety, Depression, and Quality of Life — Cagliyan Turk et al. (2024) - SCR-LIP-000169 consistent
In a study comparing lipedema patients with population controls matched for sex, age and BMI, lipedema patients reported worse self-rated general health, higher rates of self-reported depression (43.6% vs 18.5%, p=0.001) with PHQ-8 depressive symptoms in 89.7% versus 39.3% of controls, more severe pain and pain-related disability, fewer close social contacts, and a strong positive correlation between pain severity and depressive symptoms (rho=0.612, p<0.001).
Health Implications of Lipedema: Analysis of Patient Questionnaires and Population-Based Matched Controls — Kempa et al. (2024) - SCR-LIP-000170 consistent
In a survey of 98 Polish women with lipedema, all WHOQOL-BREF domains scored below general-population values (physical health 45.4, psychological 46.3, social relationships 50.4, environment 49.6 on 0-100), 59.2% had PHQ-9 scores >=10 indicating possible depression (mean PHQ-9 12.2), and core lipedema symptoms (Factor 1: leg heaviness, joint/tissue/muscle pain, swelling, stiffness) were the only significant predictor of worse quality of life (beta=-0.345, p=0.004, model explaining 23.5% of variance).
Quality of life, its factors, and sociodemographic characteristics of Polish women with lipedema — Dudek et al. (2021) - SCR-LIP-000171 consistent
In this scoping review, lipedema patients showed reduced quality of life (EQ-5D-3L 66.1 vs 85 in the Dutch population; WHOQOL-BREF physical/mental domains below midpoint), depression prevalence of 22.7%-42%, 51.1% with mental disorders, and QoL strongly correlated with depression severity (r=-0.75).
Lipoedema as a Social Problem. A Scoping Review — Czerwińska et al. (2021) · The effect of lipedema on health-related quality of life and psychological status: a narrative review of the literature — Alwardat et al. (2019) - SCR-LIP-000172 consistent
In an observational study of 26 females with lipedema versus healthy controls, lipedema patients showed markedly higher emotion regulation difficulties (DERS total 135.69±13.12 vs 53.00±9.03) and anxiety (HAM-A 27.62±8.98 vs 4.96±2.51), with all group differences remaining significant after adjusting for BMI via ANCOVA (DERS total F(1,49)=582.95, p<0.001; HAM-A F(1,49)=123.10, p<0.001).
The Difficulties in Emotional Regulation among a Cohort of Females with Lipedema — Al-Wardat et al. (2022) - SCR-LIP-000173 consistent
In 329 women with lipedema, lower quality of life (WHOQOL-BREF) was independently predicted by higher depression (PHQ-9 β=-0.36), higher appearance-related distress (DAS-24 β=-0.29), lower mobility (β=0.27) and higher symptom severity, with the final regression model explaining 73% of QoL variance and mean PHQ-9 of 11.87 indicating minor depression.
Depression and appearance-related distress in functioning with lipedema — Dudek et al. (2018) - SCR-LIP-000174 consistent
In a cross-sectional survey of 245 women with lipedema, health-related stigma was significantly higher than in an age-matched general female population (Distress 49.5 vs 17.1–28.7; 65% with moderate/severe distress) and correlated negatively with all RAND-36 quality-of-life domains (strongest for social functioning r=−0.54 and emotional well-being r=−0.50), while greater perceived social support correlated positively with HRQoL.
Health-related stigma, perceived social support, and their role in quality of life among women with lipedema — Falck et al. (2025) - SCR-LIP-000175 consistent
In a cross-sectional study of 37 women with lipedema versus 36 with lymphedema, lipedema patients showed moderate depression (PHQ-9 mean 10.4) and impaired global quality of life (LYMQOL-Leg 5.47) comparable to lymphedema patients, while lymphedema patients had worse functional status and life satisfaction; in lipedema, longer disease duration correlated with PHQ-9 (r=-0.415, p=0.028) and BMI correlated with functional impairment.
The Comparative Evaluation of Depression, Life Satisfaction, and Quality of Life Between Female Patients with Lipedema and Lymphedema — Yaman et al. (2025) - SCR-LIP-000176 consistent
In a cross-sectional cohort of 40 lipedema patients, 87.5% showed severe/high depression risk (mean HAM-D 25.39) and 92.5% showed severe/high anxiety risk (mean HAM-A 23.45), with serum vitamin D inversely correlated with depression (adjusted r=-0.580, p<0.001) and anxiety (adjusted r=-0.489, p=0.002), and BMI positively correlated with both depression (r=0.560) and anxiety (r=0.511).
The association between serum vitamin D and mood disorders in a cohort of lipedema patients — Al-Wardat et al. (2021) - SCR-LIP-000178 consistent
In 44 women with lipedema, median total SF-36 quality of life was 57.4/100 (lowest domains: general health 35, pain 47.5, social functioning 50, energy/fatigue 45), below historical healthy Polish population (61.6) and a prior lipedema cohort (59.3), and SF-36 scores did not differ by BMI or WHtR strata.
Examining the characteristic features of lipedema and the usefulness of BMI and WHtR in clinical evaluation — Czerwińska et al. (2025) - SCR-LIP-000349 consistent
In a survey of lipedema patients comparing self-reported stages, more advanced stage (3-4) was associated with higher rates of depression (48.3% vs 34.8%, p<0.001), social isolation (staying home 64.3% vs 44.4%), life dissatisfaction (35.7% vs 22.0%), and loss of mobility, while psychological burden such as inferiority complex (72.8%) and constantly thinking about lipedema (73.4%) was high across all stages.
Stages of lipoedema: experiences of physical and mental health and health care — Clarke et al. (2023) - SCR-LIP-000350 consistent
This narrative review synthesizing 25 references reports that lipedema patients show greater emotional dysregulation and higher anxiety (Al-Wardat: 26 patients vs 26 controls via DERS/HAM-A), significant behavioral disturbances versus overweight/obese controls (Chachaj et al.), depressive/anxious symptoms associated with comorbid fibromialgia (Cagliyan Turk et al.), occupational limitations in 51–73% of respondents (Clarke et al.), and that liposuction significantly reduced depressive symptoms and improved quality of life and body image (Arndt et al.).
Lipedema: The intersection of physical and mental health — Janota et al. (2025) - SCR-LIP-000351 consistent
In a systematic review and meta-analysis of cross-sectional cohorts, women with lipedema showed reduced HRQoL across all SF-36/RAND-36 domains versus population norms, with the largest deficits in energy/fatigue (43.50 vs 59.4), bodily pain (51.77 vs 77.4), role physical (51.10 vs 82.4), and general health (49.64 vs 73.1), plus impaired emotional well-being (64.19 vs 73.2) reflecting frequent anxiety/depression.
Health-related quality of life among lipedema patients: A systematic review and meta-analysis — Günay et al. (2025) - SCR-LIP-000352 consistent
In a prospective study of lipedema patients undergoing power-assisted liposuction, PHQ-4 total scores fell from 4.47 (mild depression, above population norm) to 2.10 (p<0.001), with anxiety subscale dropping 2.47→0.93 and depression subscale 2.00→1.17, while quality-of-life satisfaction (FLZM health module 45.77→88.00), self-esteem (RSES 29.93→33.33), and emotional stability all improved significantly postoperatively.
Quality of life following liposuction for lipoedema: a prospective outcome study — Klöppel et al. (2024) - SCR-LIP-000353 consistent
In a cross-sectional survey of women with lipedema (n=112), WHOQOL-BREF averaged 3.12 (1-5 scale) and life satisfaction (SWLS) averaged 3.63 (below midpoint), with symptom severity explaining 13.9% of QoL variance; psychological flexibility (AAQ-II β=0.26) and social connectedness (SCS-R β=0.37) independently predicted QoL after controlling for symptom severity, raising explained variance to 44.4%.
Quality of life in women with lipoedema: a contextual behavioral approach — Dudek et al. (2016) - SCR-LIP-000354 consistent
In a national Swedish survey of women with lipedema, RAND-36 scores were 25-35 points below the age-matched general female population across all subscales (largest gap in physical role functioning, ~43 points lower in ages 60-79; smallest in emotional well-being, ~10 points), with worse physical and social functioning at higher lipedema stages and a self-reported depression prevalence of 13.5%.
Women with lipoedema: a national survey on their health, health-related quality of life, and sense of coherence — Falck et al. (2022) - SCR-LIP-000355 consistent
In 511 lipedema patients, PHQ-9 averaged 10.84±6.39 with 54% at risk of moderate-to-severe depression, WHOQOL-BREF global score averaged 60.5±16.02 (lowest in physical 54.54 and psychological 51.91 domains), and quality-of-life impairment correlated with disease stage (r=0.55, p<0.001) and inversely with depression score (r=-0.775, p<0.0001).
Characteristics and Patient Reported Outcome Measures in Lipedema Patients—Establishing a Baseline for Treatment Evaluation in a High-Volume Center — Hamatschek et al. (2022) · Understanding the Vicious Circle of Pain, Physical Activity, and Mental Health in Lipedema Patients – a Response Surface Analysis — Aitzetmüller-Klietz et al. (2023) - SCR-LIP-000356 consistent
In a survey of lipedema patients, RAND-36 quality of life was significantly lower than the general Dutch female population (59.3 vs 74.9, p<0.001) and EQ-5D-3L was reduced (66.1 vs 85), with 42.0% reporting anxiety/depression and 74.1% reporting pain/discomfort (vs 31.1% in the general population).
Exploration of Patient Characteristics and Quality of Life in Patients with Lipoedema Using a Survey — Romeijn et al. (2018) - SCR-LIP-000357 consistent
In a Swiss cohort of 239 lipedema patients assessed with validated questionnaires, 64.4% had anxiety (HADS≥8), 23.4% had depression (HADS≥8), and low quality of life was found in 71.5% (PCS-SF36) and 67.4% (MCS-SF36), with none of these psychosocial parameters differing significantly across disease stages (p>0.5).
Clinical characteristics, comorbidities, and correlation with advanced lipedema stages: A retrospective study from a Swiss referral centre — Luta et al. (2025)
Conflicting claims
- None indexed yet.
Refining / contextual
- SCR-LIP-000177 refines
Compared with overweight/obese women, women with lipedema showed greater disability (WHO-DAS II domains for mobility, household activities, and social participation remained significantly worse after robust BMI adjustment, e.g. social participation Z=3.15, p=0.002; days with difficulties Z=4.13, p<0.001), but showed NO significant differences in depression (BDI-II median 11 vs 8, p=0.130; HADS-D p=0.474) or anxiety (HADS-A 9.16 vs 8.10, p=0.162), before or after BMI adjustment.
Disability and emotional symptoms in women with lipedema: A comparison with overweight/obese women — Chachaj et al. (2024) - SCR-LIP-000103 context
Lipoedema as a Social Problem. A Scoping Review
Lipoedema as a Social Problem. A Scoping Review — Czerwińska et al. (2021)
Major uncertainty
It remains uncertain whether elevated depression and anxiety in lipedema are disease-specific or substantially attributable to comorbid obesity; whether disease stage reliably predicts psychosocial burden (moderate-grade evidence suggests it does not); what the causal direction is between pain, mood, and QoL; and whether any treatment (including liposuction) produces durable, disease-modifying psychosocial benefit. No RCTs exist.
Version history
- SQ-LIP-000020 · v1.5 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000020 · v1.4 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000020 · v1.3 — 2026-05-31 — This update added a moderate-grade systematic review/meta-analysis quantifying HRQoL deficits, several additional large cross-sectional cohorts (including n=511 and a 239-patient Swiss cohort showing 64.4% anxiety and no stage-dependence), two narrative reviews, a Swedish national survey, and the first prospective (uncontrolled) liposuction data suggesting post-operative improvement in mood and QoL. · view this version
- SQ-LIP-000020 · v1.2 — 2026-05-31 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000020 · v1.1 — 2026-05-31 — This update established the first answer for this question by indexing 12 observational studies/reviews showing reduced quality of life and elevated depression/anxiety in lipedema, while adding a key moderate-grade refinement that mood differences may disappear when comparing against BMI-matched overweight/obese controls. · view this version
- SQ-LIP-000020 · v1.0 — 2026-05-31 — Question created (promoted from SQ-LIP-D000005). · snapshot not archived
Key references
DOI:10.3389/fgwh.2025.1629077 · DOI:10.1089/lrb.2023.0038 · DOI:10.3390/life14030295 · DOI:10.1186/s12905-021-01174-y · DOI:10.3390/ijerph181910223 · DOI:10.1007/s40519-019-00703-x · DOI:10.3390/ijerph192013679 · DOI:10.1080/13548506.2018.1459750 · DOI:10.1080/07399332.2025.2499487 · DOI:10.1089/lrb.2024.0117 · DOI:10.1515/hmbci-2021-0027 · DOI:10.17219/acem/181146 · DOI:10.1186/s12905-025-03834-9 · DOI:10.1007/s11136-022-03216-w · DOI:10.12740/app/201427 · DOI:10.1177/02683555251410009 · DOI:10.1016/j.bjps.2024.02.048 · DOI:10.1007/s11136-015-1080-x · DOI:10.1186/s12905-022-02022-3 · DOI:10.3390/jcm11102836 · DOI:10.21203/rs.3.rs-2705753/v1 · DOI:10.1007/s13555-018-0241-6 · DOI:10.1371/journal.pone.0319099